Apellis Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic compounds that inhibit the complement system to... Apellis Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic compounds that inhibit the complement system to treat autoimmune and inflammatory diseases. Its key products include EMPAVELI, approved for paroxysmal nocturnal hemoglobinuria, cold agglutinin disease, C3 glomerulopathy, immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE, indicated for geographic atrophy secondary to age-related macular degeneration. The company targets complement-mediated rare diseases in ophthalmology, hematology, and nephrology through its C3 complement science platform. Apellis Pharmaceuticals Inc. maintains collaborations, such as with Swedish Orphan Biovitrum AB for pegcetacoplan development and commercialization, and with Beam Therapeutics Inc. for base editing technologies in complement-driven diseases. Founded in 2009 and headquartered in Waltham, Massachusetts, it plays a significant role in advancing targeted therapies for conditions with high unmet medical needs in the biopharmaceutical sector.Show lessShow more

Disclosures ESG Data Financial Data

GHG Emissions Climate Targets EU Taxonomy Energy Waste Management

Data not available

Energy Management data not yet covered for Apellis Pharmaceuticals

We have not yet reviewed Apellis Pharmaceuticals's disclosures for Energy Management data.

If this data is relevant to your work, you can submit a data coverage request and our team will investigate the company's disclosures and capture the data if available.

Would you like us to review Apellis Pharmaceuticals's data?

Start your 30-day free trial to request a data review for Apellis Pharmaceuticals.

Start Free Trial

Legal Center Contact Us

Apellis Pharmaceuticals Inc

Energy Management data not yet covered for Apellis Pharmaceuticals

Account Restricted